Outcomes of Early Esophageal Adenocarcinoma with Lymphovascular Invasion Following Endoscopic Submucosal Dissection: A Multicenter Retrospective Series
Background and Aims Endoscopic submucosal dissection (ESD) is an accepted treatment option for early esophageal adenocarcinoma (EAC) with negligible risk of lymph node metastasis (LNM). Lymphovascular invasion (LVI) is a known risk factor for LNM, and surgery (SR) is recommended. However, real-life data on long-term follow-up after endoscopic resection (ER) of EAC with LVI are scarce. The aim of this study was to analyze the clinical course of patients after ER of EAC with LVI. Methods Patients from 16 German centers were included when ESD specimens showed EAC with LVI and R0 resection. Outcome parameters were survival and the rate of metastasis during follow-up. Analysis was performed retrospectively from a prospective database. Results 23 patients were included. 14/23 (60.9%) underwent endoscopic follow-up (EFU) while 9/23 (39.1%) were treated with additional SR after ESD. The EFU group included more ASA 3/4 patients (64.3% vs. 11.1%), fewer lesions with submucosal invasion (35.7% vs. 66.7%) and fewer lesions with poor differentiation (28.6% vs. 66.7%). In the EFU group, 4/14 patients died during follow-up (related to ESD n = 1, metastatic recurrence of EAC n = 1, unrelated to EAC n = 2). No deaths or recurrences were observed in the SR group. The LNM rate was 44.4% (4/9) in surgical specimens. Mean follow-up was 34 months. Conclusion LVI indicates a high risk of LNM in early EAC. However, in clinical practice a substantial portion of affected patients do not undergo surgery, and only a minority die from EAC. The data underscore the need for individualized treatment decisions — especially in elderly and comorbid patients.
Authors
- Andreas Wannhoff (ORCID: https://orcid.org/0000-0002-9660-1323)
- Anna Muzalyova (ORCID: https://orcid.org/0000-0003-4441-8006)
- Viktor Rempel
- Carola Fleischmann (ORCID: https://orcid.org/0000-0001-5894-3800)
- Andreas Probst (ORCID: https://orcid.org/0000-0002-1486-9298)
- Alanna Ebigbo (ORCID: https://orcid.org/0000-0001-7765-035X)
- Ingo Steinbrück (ORCID: https://orcid.org/0000-0001-9056-8844)
- Helmut Messmann (ORCID: https://orcid.org/0000-0002-4026-6837)
- Dani Dakkak
- Siegbert Faiss (ORCID: https://orcid.org/0000-0002-9920-3582)
- Hans‐Peter Allgaier
- Jörg R. J. Schirra (ORCID: https://orcid.org/0000-0002-6887-2791)
- Johanna Schreiber
Institutions
- University Hospital Augsburg (DE)
- Elisabeth-Krankenhaus Essen (DE)
- Sana Klinikum Lichtenberg (DE)
- St. Josef-Hospital (DE)
- Evangelisches Diakoniekrankenhaus (DE)
- Klinikum Ludwigsburg (DE)
- Asklepios Klinik Barmbek (DE)
- St. Anna Hospital (DE)
- Ludwig-Maximilians-Universität München (DE)
- Ruhr University Bochum (DE)
Publication Details
- Journal
- Journal of Gastrointestinal Cancer
- Published
- 2026-11-21
- DOI
- https://doi.org/10.1007/s12029-026-01631-7
- Primary Topic
- Esophageal Cancer Research and Treatment
- Type
- article
- Field-Weighted Citation Impact
- 0.00